The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Remifentanil 1 mg powder for concentrate for solution for injection or infusion

Fresenius Kabi Deutschland GmbHPA2059/056/001

Main Information

Trade NameRemifentanil 1 mg powder for concentrate for solution for injection or infusion
Active SubstancesRemifentanil
Dosage FormPowder for concentrate for solution for injection/infusion
Licence HolderFresenius Kabi Deutschland GmbH
Licence NumberPA2059/056/001

Group Information

ATC CodeN01AH Opioid anesthetics
N01AH06 remifentanil


License statusAuthorised
Licence Issued01/10/2010
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in schedule 2 to the Misuse of Drugs Regulations 2017.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back